PS-002 for the Treatment of IgA Nephropathy in Adults | MicrobiomeTrials← Back to trialsNCT07182227
PS-002 for the Treatment of IgA Nephropathy in Adults
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-03-30Est. Completion: 2028-09
Enrollment target: 32 participants Locations- University of Miami Hospital, Miami, Florida, United States
- The Johns Hopkins Hospital, Baltimore, Maryland, United States
- Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Leicester General Hospital, Leicester, Leicestershire, United Kingdom
- Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
- Southmead Hospital, Bristol, United Kingdom
- Cardiff and Vale University Health Board, Cardiff, United Kingdom
- Royal Infirmary of Edinburgh Clinical Research Facility, Edinburgh, United Kingdom
- The Royal London Hospital, London, United Kingdom
Other microbiome trials you might be interested in
Primary Immunoglobulin A Nephropathy (IgAN)
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetic…
Madera, United StatesEst. completion Jun 28, 2030
Lupus Nephritis
A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharma…
Hefei, ChinaCompleted Jun 8, 2026